Porous paclitaxel matrices and methods of manufacture thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/70
A61F-002/00
출원번호
US-0213257
(2005-08-26)
등록번호
US-RE40493
(2008-09-09)
발명자
/ 주소
Straub,Julie A.
Bernstein,Howard
Chickering, III,Donald E.
Khattak,Sarwat
Randall,Greg
출원인 / 주소
Acusphere, Inc.
대리인 / 주소
Pabst Patent Group LLP
인용정보
피인용 횟수 :
6인용 특허 :
44
초록▼
Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combini
Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.
대표청구항▼
We claim: 1. A pharmaceutical composition comprising a porous matrix formed of a hydrophilic excipient, a wetting agent and nanoparticles and microparticles of a taxane, wherein the nanoparticles and microparticles have a mean diameter between about 0.01 and 5 μm and a total surface area great
We claim: 1. A pharmaceutical composition comprising a porous matrix formed of a hydrophilic excipient, a wetting agent and nanoparticles and microparticles of a taxane, wherein the nanoparticles and microparticles have a mean diameter between about 0.01 and 5 μm and a total surface area greater than about id="DEL-S-00001" date="20080909" 0.5 m2id="DEL-S-00001" id="INS-S-00003" date="20080909" 0.5 m2/mLid="INS-S-00003" , wherein the porous matrix is in a dry powder form, and wherein upon exposure to an aqueous medium, the matrix dissolves to leave the taxane nanoparticles and microparticles, wherein the dissolution rate of the taxane nanoparticles and microparticles in an aqueous solution is increased relative to unprocessed taxane. 2. The composition of claim 1, wherein the matrix is made by a process comprising (a) dissolving a taxane in a volatile solvent to form a taxane solution, (b) combining at least one pore forming agent, a wetting agent, and a hydrophilic excipient with the taxane solution to form an emulsion, suspension, or second solution, and (c) removing the volatile solvent and the pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix. 3. The composition of claim 2 wherein the pore forming agent is a volatile salt. 4. The composition of claim 1 wherein the porous matrix is in a dry powder form having a TAP density less than or equal to 1.0 g/mL. 5. The composition of claim 1, wherein the matrix comprises at least one excipient selected from the group consisting of hydrophilic polymers, sugars, tonicity agents, pegylated excipients, and combination thereof. 6. The composition of claim 1 wherein the mean diameter of the taxane microparticles is between about 0.50 and 5 μm. 7. A taxane suspension comprising the composition of claim 1 added to an aqueous solution suitable for parenteral administration. 8. The composition of claim 1 wherein the matrix is processed into tablets or capsules suitable for oral administration. 9. The composition of claim 1 wherein the matrix is formed into suppositories suitable for vaginal or rectal administration. 10. The composition of claim 1 wherein the matrix is in a dry powder form suitable for pulmonary administration. 11. A method for making a porous matrix of a taxane comprising (a) dissolving a taxane in a volatile solvent to form a taxane solution, (b) combining at least one pore forming agent, a wetting agent, and a hydrophilic excipient with the taxane solution to form an emulsion, suspension, or second solution, and (c) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix comprising nanoparticles and microparticles of taxane, wherein the dissolution rate of the taxane nanoparticles and microparticles in an aqueous solution is increased relative to unprocessed taxane. 12. The method of claim 11 wherein the wetting agent is a polyoxyethylene sorbitan fatty acid ester. 13. The method of claim 11 wherein step (c) is conducted using a process selected from spray drying, evaporation, fluid bed drying, lyophilization, vacuum drying, or a combination thereof. 14. The method of claim 11 wherein the taxane solution or pore forming agent comprises excipients selected from the group consisting of hydrophilic excipients, pegylated excipients, and tonicity agents. 15. The method of claim 11 wherein the pore forming agent is a volatile salt. 16. The method of claim 15 wherein the volatile salt is selected from the group consisting of ammonium bicarbonate, ammonium acetate, ammonium chloride, ammonium benzoate, and mixtures thereof. 17. A method of treating a patient with a taxane, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a taxane id="INS-S-00004" date="20080909" to provide anticancer or antitumor activity id="INS-S-00004" in a formulation comprising a porous matrix formed of a hydrophilic excipient, a wetting agent and nanoparticles and microparticles of a taxane, wherein the nanoparticles and microparticles have a mean diameter between about 0.01 and 5 μm and a total surface area greater than about 0.5 m2/mL, and wherein the porous matrix is in a dry powder form having a TAP density less than or equal to 1.0 g/mL wherein upon exposure to an aqueous medium, the matrix dissolves to leave the taxane nanoparticles and microparticles wherein the dissolution id="DEL-S-00002" date="20080909" rareid="DEL-S-00002" id="INS-S-00005" date="20080909" rate id="INS-S-00005" of the taxane nanoparticles and microparticles in an aqueous solution is increased relative to unprocessed taxane. 18. The method of claim 17 wherein the formulation is suitable for administration by a route selected from the group consisting of parenteral, mucosal, oral, and topical administration. 19. The method of claim 18 wherein the parenteral route is selected from the group consisting of intravenous, intraarterial, intracardiac, intrathecal, intraosseous, intraarticular, intrasynovial, intracutaneous, subcutaneous, and intramuscular administration. 20. The method of claim 18 wherein the mucosal route is selected from the group consisting of pulmonary, buccal, sublingual, intranasal, rectal, and vaginal administration. 21. The method of claim 18 wherein the formulation is suitable for intraocular or conjunctival administration. 22. The method of claim 18 wherein the formulation is suitable for intracranial, intralesional, or intratumoral administration. 23. The method of claim 18 wherein the formulation is in an aqueous solution suitable for parenteral administration. 24. The method of claim 18 wherein the formulation is in a tablet or capsule suitable for oral administration. 25. The method of claim 18 wherein the formulation is in a suppository suitable for vaginal or rectal administration. 26. The method of claim 18 wherein the formulation is a dry powder suitable for pulmonary administration. 27. The composition of claim 1 wherein the taxane is paclitaxel. 28. The method of claim 11 wherein the taxane is paclitaxel. 29. The method of claim 17 wherein the taxane is paclitaxel. 30. The composition of claim 1 wherein the hydrophilic excipient is selected from the group consisting of water soluble polymers and sugars, and the wetting agent is a surfactant. 31. The method of claim 11 wherein the hydrophilic excipient is selected from the group consisting of water soluble polymers and sugars, and the wetting agent is a surfactant. 32. The method of claim 17 wherein the hydrophilic excipient is selected from the group consisting of water soluble polymers and sugars, and the wetting agent is a surfactant. id="INS-S-00006" date="20080909" 33. A method for making a porous matrix comprising nanoparticles and microparticles of paclitaxel, the method comprising (a) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (b) combining at least one pore forming agent including ammonium bicarbonate, a polyoxyethylene sorbitan fatty acid ester, and polyvinylpyrrolidone with the paclitaxel solution to form an emulsion, suspension, or second solution, and (c) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix comprising nanoparticles and microparticles of paclitaxel, wherein the dissolution rate of the paclitaxel nanoparticles and microparticles in an aqueous solution is increased relative to unprocessed paclitaxel.id="INS-S-00006" id="INS-S-00007" date="20080909" 34. The method of claim 33, wherein the polyoxyethylene sorbitan fatty acid ester is polysorbate 80.id="INS-S-00007" id="INS-S-00008" date="20080909" 35. The method of claim 33, wherein step (b) further comprises adding a sugar to the paclitaxel solution.id="INS-S-00008" id="INS-S-00009" date="20080909" 36. The method of claim 35, wherein the sugar is mannitol.id="INS-S-00009" id="INS-S-00010" date="20080909" 37. A pharmaceutical composition comprising a porous matrix formed of polyvinylpyrrolidone, a polyoxyethylene sorbitan fatty acid ester and nanoparticles and microparticles of paclitaxel, wherein the nanoparticles and microparticles have a mean diameter between about 0.01 and 5 μm and a total surface area greater than about 0.5 m2/mL, wherein the porous matrix is in a dry powder form, and wherein upon exposure to an aqueous medium, the matrix dissolves to leave the paclitaxel nanoparticles and microparticles, wherein the dissolution rate of the paclitaxel nanoparticles and microparticles in an aqueous solution is increased relative to unprocessed paclitaxel.id="INS-S-00010" id="INS-S-00011" date="20080909" 38. The composition of claim 37, wherein the polyoxyethylene sorbitan fatty acid ester is polysorbate 80.id="INS-S-00011" id="INS-S-00012" date="20080909" 39. The composition of claim 37, further comprising a sugar.id="INS-S-00012" id="INS-S-00013" date="20080909" 40. The composition of claim 39, wherein the sugar is mannitol.id="INS-S-00013" id="INS-S-00014" date="20080909" 41. A method of treating a patient with a paclitaxel formulation, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of paclitaxel to provide anticancer or antitumor activity in a formulation comprising a porous matrix formed of polyvinylpyrrolidone, a polyoxyethylene sorbitan fatty acid ester and nanoparticles and microparticles of paclitaxel, wherein the nanoparticles and microparticles have a mean diameter between about 0.01 and 5 μm and a total surface area greater than about 0.5 m2/mL, and wherein the porous matrix is in a dry powder form having a TAP density less than or equal to 1.0 g/mL, wherein upon exposure to an aqueous medium, the matrix dissolves to leave the paclitaxel nanoparticles and microparticles wherein the dissolution rate of the paclitaxel nanoparticles and microparticles in an aqueous solution is increased relative to unprocessed taxane.id="INS-S-00014" id="INS-S-00015" date="20080909" 42. The method of claim 41, wherein the polyoxyethylene sorbitan fatty acid ester is polysorbate 80.id="INS-S-00015" id="INS-S-00016" date="20080909" 43. The method of claim 41, wherein the formulation further comprises a sugar.id="INS-S-00016" id="INS-S-00017" date="20080909" 44. The method of claim 43, wherein the sugar is mannitol.id="INS-S-00017" id="INS-S-00018" date="20080909" 45. The composition of claim 1, wherein the hydrophilic excipient is the wetting agent.id="INS-S-00018" id="INS-S-00019" date="20080909" 46. The method of claim 11, wherein the hydrophilic excipient is the wetting agent.id="INS-S-00019" id="INS-S-00020" date="20080909" 47. The method of claim 17 wherein the hydrophilic excipient is the wetting agent.id="INS-S-00020"
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (44)
Wiedmann Timothy S. ; Wood Ray W. ; DeCastro Lan, Aerosols containing beclomethazone nanoparticle dispersions.
Bagchi Pranab (Webster NY) Scaringe Raymond P. (Rochester NY) Bosch H. William (Bryn Mawr PA), Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers.
Bermudes, David G.; King, Ivan C.; Clairmont, Caroline A.; Lin, Stanley L.; Belcourt, Michael, Compositions and methods for tumor-targeted delivery of effector molecules.
Eickhoff W. Mark (Downingtown PA) Mueller Karl R. (Pexton PA) Engers David A. (Collegeville PA), Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids.
Bruno Joseph A. (Blue Bell PA) Doty Brian D. (Phoenixville PA) Gustow Evan (Ardmore PA) Illig Kathleen J. (Phoenixville PA) Rajagopalan Nats (Phoenixville PA) Sarpotdar Pramod (Malvern PA), Method of grinding pharmaceutical substances.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation.
Bagchi Pranab (Webster NY) Stewart Robert C. (Spencerport NY) McIntire Gregory L. (West Chester PA) Minter John R. (Rochester NY), Microprecipitation of micro-nanoparticulate pharmaceutical agents.
Bagchi Pranab (Webster NY) Karpinski Piotr H. (Fairport NY) McIntire Gregory L. (West Chester PA), Microprecipitation of nanoparticulate pharmaceutical agents.
Bagchi Pranab ; McIntire Gregory L. ; Minter John R., Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmace.
Wong Sui-Ming (Collegeville PA) Cooper Eugene R. (Berwyn PA) Xu Shugian (Exton PA), Polyalkylene block copolymers as surface modifiers for nanoparticles.
Mathiowitz Edith (Brookline MA) Langer Robert S. (Somerville MA) Warshawsky Abraham (Rehovot MA ILX) Edelman Elazar (Brookline MA), Polymer composite for controlled release or membrane formation.
Dugstad Harald,NOX ; Foss Per Antonius,NOX ; Klaveness Jo,NOX ; Rongved P.ang.l,NOX ; Skurtveit Roald,NOX, Polymeric surfactant-encapsulated microbubbles and their use in ultrasound imaging.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Bosch H. William (Bryn Mawr PA) Marcera Donna M. (Collegeville PA) Mueller Ronald L. (Downingtown PA) Swanson Jon R. (Macungie PA) Mishra Dinesh S. (Harleysville PA), Process for preparing therapeutic compositions containing nanoparticles.
Desai Neil P. ; Tao Chunlin ; Yang Andrew ; Louie Leslie ; Zheng Tianli ; Yao Zhiwen ; Soon-Shiong Patrick ; Magdassi Shlomo,ILX, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Ruddy Stephen B. (Schwenksville PA) Eickhoff W. Mark (Downingtown PA) Liversidge Gary (West Chester PA), Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylen.
Wong Sui-Ming (Collegeville PA) Newington Ian M. (Hazlemere GB2) Liversidge Elaine M. (West Chester PA) McIntire Gregory L. (West Chester PA) Pitt Alan R. (Sandridge GBX) Shaw Jack M. (Aberdeen MD), Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions.
Liversidge Gary G. (West Chester PA) Conzentino ; Jr. Philip (West Chester PA) Cundy Kenneth C. (Pottstown PA) Sarpotdar Pramod P. (Malvern PA), Surface modified NSAID nanoparticles.
Straub, Julie; Altreuter, David; Bernstein, Howard; Chickering, III, Donald E.; Khattak, Sarwat; Randall, Greg, Porous drug matrices and methods of manufacture thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.